Distinguished in WT1-Related Wilms Tumor Syndromes

Dr. Stephen J. Savage

Urology
MUSC Health
University Medical Associates Of The Medical University Of South Carol
171 Ashley Ave, 
Charleston, SC 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth

Distinguished in WT1-Related Wilms Tumor Syndromes
MUSC Health
University Medical Associates Of The Medical University Of South Carol
171 Ashley Ave, 
Charleston, SC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Stephen Savage is an Urologist in Charleston, South Carolina. Dr. Savage is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Ureterocele, Nephrectomy, and Reconstructive Urology Surgery. Dr. Savage is currently accepting new patients.

His clinical research consists of co-authoring 45 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Urology
Licenses
Urology in SC
Hospital Affiliations
Tidelands Waccamaw Community Hospital
Musc Health Columbia Medical Center Downtown
Musc Medical Center
Kershawhealth
Musc Health Florence Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Absolute Total Care South Carolina
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Clover Health
  • INSURANCE PLAN
  • MEDICARE MAPD
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
HMSA
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

UNIVERSITY MEDICAL ASSOCIATES OF THE MEDICAL UNIVERSITY OF SOUTH CAROL
171 Ashley Ave, Charleston, SC 29425
Call: 843-792-1414

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


12 Clinical Trials

LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)
LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)
Enrollment Status: Recruiting
Publish Date: March 13, 2025
Intervention Type: Drug
Study Drug: Screening Platform
Study Phase: Phase 2/Phase 3
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Carboplatin, Pembrolizumab, Pemetrexed
Study Phase: Phase 3
S1803, Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients With Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
S1803, Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients With Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
Enrollment Status: Active_not_recruiting
Publish Date: September 15, 2025
Intervention Type: Drug
Study Drugs: Lenalidomide, Daratumumab/rHuPH20
Study Phase: Phase 3
A Phase III Double Blinded Study of Early Intervention After RADICAl ProstaTEctomy With Androgen Deprivation Therapy With or Without Darolutamide vs. Placebo in Men at Highest Risk of Prostate Cancer Metastasis by Genomic Stratification (ERADICATE)
A Phase III Double Blinded Study of Early Intervention After RADICAl ProstaTEctomy With Androgen Deprivation Therapy With or Without Darolutamide vs. Placebo in Men at Highest Risk of Prostate Cancer Metastasis by Genomic Stratification (ERADICATE)
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2025
Intervention Type: Other, Drug
Study Drugs: Darolutamide, Goserelin acetate, Leuprolide acetate, Triptorelin
Study Phase: Phase 3
Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Gemcitabine Hydrochloride, Pembrolizumab
Study Phase: Phase 2
A Randomized Controlled Trial of ProstAtak® as Adjuvant to Up-front Radiation Therapy For Localized Prostate Cancer
A Randomized Controlled Trial of ProstAtak® as Adjuvant to Up-front Radiation Therapy For Localized Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 30, 2025
Intervention Type: Biological
Study Drugs: Aglatimagene besadenovec, Valacyclovir
Study Phase: Phase 3
A Randomized Controlled Trial Of AdV-tk + Valacyclovir Administered During Active Surveillance For Newly Diagnosed Prostate Cancer
A Randomized Controlled Trial Of AdV-tk + Valacyclovir Administered During Active Surveillance For Newly Diagnosed Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 30, 2025
Intervention Type: Biological, Drug
Study Drugs: Aglatimagene Besadenovec, Valacyclovir
Study Phase: Phase 2
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Enrollment Status: Active_not_recruiting
Publish Date: July 28, 2025
Intervention Type: Other, Biological, Procedure
Study Drug: Nivolumab
Study Phase: Phase 3
Olanzapine With or Without Fosaprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)in Patients Receiving Highly Emetogenic Chemotherapy (HEC): A Phase III Randomized, Double Blind, Placebo-Controlled Trial
Olanzapine With or Without Fosaprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)in Patients Receiving Highly Emetogenic Chemotherapy (HEC): A Phase III Randomized, Double Blind, Placebo-Controlled Trial
Enrollment Status: Completed
Publish Date: April 06, 2025
Intervention Type: Other, Drug
Study Phase: Phase 3
S1602, A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming With Intradermal BCG Before Intravesical Therapy for BCG-Naive High-Grade Non-muscle Invasive Bladder Cancer
S1602, A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming With Intradermal BCG Before Intravesical Therapy for BCG-Naive High-Grade Non-muscle Invasive Bladder Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 02, 2025
Intervention Type: Biological, Other
Study Drugs: Bacillus of Calmette-Guerin, Bacillus of Calmette-Guerin Tokyo-172 Strain Solution, Bacillus of Calmette-Guerin Tokyo-172 Strain Vaccine
Study Phase: Phase 3
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Other
Study Phase: Phase 3
Two-Part Prospective Study to Measure Impact of Prolaris® Testing Added to Treatment Decision Following Biopsy in Newly Diagnosed Prostate Cancer Patients to Measure Prediction of Progression/Recurrence in Men Treated at VAMC
Two-Part Prospective Study to Measure Impact of Prolaris® Testing Added to Treatment Decision Following Biopsy in Newly Diagnosed Prostate Cancer Patients to Measure Prediction of Progression/Recurrence in Men Treated at VAMC
Enrollment Status: Terminated
Publish Date: June 13, 2022
Intervention Type: Behavioral
View 11 Less Clinical Trials

45 Total Publications

Unveiling Racial Disparities in Localized Prostate Cancer: A Systems-Level Exploration of the lncRNA Landscape.
Unveiling Racial Disparities in Localized Prostate Cancer: A Systems-Level Exploration of the lncRNA Landscape.
Journal: Genes
Published: December 29, 2024
View All 45 Publications
Similar Doctors
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Theodore E. Brisson
Urology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Theodore E. Brisson
Urology

Palmetto Adult And Childrens Urology PA

2890 Tricom St, 
N Charleston, SC 
 (11.6 miles away)
843-797-6600
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Theodore Brisson is an Urologist in N Charleston, South Carolina. Dr. Brisson is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Urinary Incontinence, Urinary Tract Infection in Children, Urinary Tract Infection (UTI), Nephrectomy, and Reconstructive Urology Surgery. Dr. Brisson is currently accepting new patients.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. John B. Adams
Urology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. John B. Adams
Urology

University Medical Associates Of The Medical University Of South Carol

171 Ashley Ave, 
Charleston, SC 
 (0.1 miles away)
843-792-1414
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

John Adams is an Urologist in Charleston, South Carolina. Dr. Adams is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Perirenal Abscess, Ureteroscopy, and Prostatectomy. Dr. Adams is currently accepting new patients.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Eric M. Wallen
Urology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Eric M. Wallen
Urology

University Medical Associates Of The Medical University Of South Carol

171 Ashley Ave, 
Charleston, SC 
 (0.1 miles away)
843-792-1414
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Eric Wallen is an Urologist in Charleston, South Carolina. Dr. Wallen is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Renal Cell Carcinoma (RCC), Bladder Cancer, Prostate Cancer, Cystectomy, and Nephrectomy. Dr. Wallen is currently accepting new patients.

VIEW MORE WT1-RELATED WILMS TUMOR SYNDROMES DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Savage's expertise for a condition
ConditionClose
    • Distinguished
    • Bladder Cancer
      Dr. Savage is
      Distinguished
      . Learn about Bladder Cancer.
      See more Bladder Cancer experts
    • Boils
      Dr. Savage is
      Distinguished
      . Learn about Boils.
      See more Boils experts
    • Chromophobe Renal Cell Carcinoma
      Dr. Savage is
      Distinguished
      . Learn about Chromophobe Renal Cell Carcinoma.
      See more Chromophobe Renal Cell Carcinoma experts
    • Clear Cell Sarcoma
      Dr. Savage is
      Distinguished
      . Learn about Clear Cell Sarcoma.
      See more Clear Cell Sarcoma experts
    • Familial Prostate Cancer
      Dr. Savage is
      Distinguished
      . Learn about Familial Prostate Cancer.
      See more Familial Prostate Cancer experts
    • Familial Wilms Tumor 2
      Dr. Savage is
      Distinguished
      . Learn about Familial Wilms Tumor 2.
      See more Familial Wilms Tumor 2 experts
    View All 16 Distinguished Conditions
    • Advanced
    • Bilateral Hydronephrosis
      Dr. Savage is
      Advanced
      . Learn about Bilateral Hydronephrosis.
      See more Bilateral Hydronephrosis experts
    • Bladder Stones
      Dr. Savage is
      Advanced
      . Learn about Bladder Stones.
      See more Bladder Stones experts
    • Carbuncle
      Dr. Savage is
      Advanced
      . Learn about Carbuncle.
      See more Carbuncle experts
    • Empyema
      Dr. Savage is
      Advanced
      . Learn about Empyema.
      See more Empyema experts
    • Enlarged Prostate (BPH)
      Dr. Savage is
      Advanced
      . Learn about Enlarged Prostate (BPH).
      See more Enlarged Prostate (BPH) experts
    • Folliculitis
      Dr. Savage is
      Advanced
      . Learn about Folliculitis.
      See more Folliculitis experts
    View All 18 Advanced Conditions
    • Experienced
    • Acute Cystitis
      Dr. Savage is
      Experienced
      . Learn about Acute Cystitis.
      See more Acute Cystitis experts
    • Autosomal Dominant Polycystic Kidney Disease
      Dr. Savage is
      Experienced
      . Learn about Autosomal Dominant Polycystic Kidney Disease.
      See more Autosomal Dominant Polycystic Kidney Disease experts
    • Bladder Outlet Obstruction
      Dr. Savage is
      Experienced
      . Learn about Bladder Outlet Obstruction.
      See more Bladder Outlet Obstruction experts
    • Congenital Mesoblastic Nephroma
      Dr. Savage is
      Experienced
      . Learn about Congenital Mesoblastic Nephroma.
      See more Congenital Mesoblastic Nephroma experts
    • Frequent or Urgent Urination
      Dr. Savage is
      Experienced
      . Learn about Frequent or Urgent Urination.
      See more Frequent or Urgent Urination experts
    • Hereditary Paraganglioma-Pheochromocytoma Syndrome
      Dr. Savage is
      Experienced
      . Learn about Hereditary Paraganglioma-Pheochromocytoma Syndrome.
      See more Hereditary Paraganglioma-Pheochromocytoma Syndrome experts
    View All 17 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2025 All Rights Reserved